Hi mate, as a long time holder, I share your and Big Daniel’s...

Hi mate, as a long time holder, I share your and Big Daniel’s concerns and frustrations. There is obviously a great deal of activity taking place in this burgeoning industry at the moment. Although we are currently not trading, CGB are clearly still engaged in taking the company forward by negotiating joint ventures and other significant deals (the Biohealth joint venture is an example of this). However I believe the number one priority for the company should be getting the company re-listed. Personally, I would prefer to defer one such joint venture or other deal if it meant that we could re-list that much quicker.

We as shareholders have for too long been denied the right to see how the market perceives the value of the seemingly significant deals the company has negotiated whilst in suspension, in the form of hopefully upward movement in the share price.

Although we have Neil trying to do his best under what I imagine to be difficult circumstances, I do believe that we could have been given more information on the exact nature of the specific tasks to be completed, which have caused these continual and lengthy delays. I am aware that Neil and the company must abide by very strict rules under the whole regulatory framework in which the company operates, however I don’t believe I have seen a brief, clear and concise summary of where the company currently stands and what it’s next tasks and priorities are.

As an example of this, the company has changed the way in which the funds from the Capital Raise are to be used, from the fit-out of the indoor facility via the Medcan deal, to using those monies in hopefully taking us forward under the Biohealth joint venture.

It would seem to me likely that the ASX may require shareholders’ approval of this and the calling of an EGM (perhaps someone has a greater knowledge in this area). If this is indeed the case, the Corporations Act requires at least 28 days notice be given of the meeting, which in itself could put back re-listing yet again.

I do not recall  a statement from the company stating that such an EGM may be required.

It would seem to me to be a reasonable expectation of the shareholders that we should be informed of the broad next steps in this lengthy process, beyond the BoD simply thanking the shareholders for their ‘patience’.

Having said all of the above, I remain committed to see CGB progress and hopefully take us all forward. I would simply like more meaningful information to be supplied by the company.

GLTAH & DYOR.